Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5911523 | 0.86 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5911522 | 0.85 | CTSD (0.49) | CTSDCNR2KCNK3KCNK9STAT3 | |
| SCHEMBL2677179 | 0.83 | CTSD (0.44) | CTSDCNR2KCNK3KCNK9RXFP1 | |
| SCHEMBL9712494 | 0.79 | MAPT (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2677857 | 0.78 | CES2 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2318839 | 0.77 | CNR2 (0.46) | CNR2HTT | |
| SCHEMBL322168 | 0.77 | CTSD (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29658169 | 0.77 | CTSD (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28516342 | 0.76 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7256990 | 0.76 | TP53 (0.49) | CTSDCNR2KCNK3KCNK9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800607-B2 | IMPROVED PHARMACOLOGICAL ACTIVITIES, PHARMACOKINETICS AND PHYSICAL PROPERTIES; MODIFIED WITH 1-ACYL-GLYCEROL DERIVATIVE | LTT BIO-PHARMA CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20030073631-A1 | Modified bdnf | LTT BIO-PHARMA CO., LTD. (JP) | 2003-04-17 | — | — | US | disclosed |
| US-6096741-A | FUNGICIDES, TACHYKININ ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073631-A1 | Modified bdnf | BDNF, NTRK2, NGF | CA12 3852/4885CA1 4271/4885CA2 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.